| miR-100 |
hsa05200:Pathways in cancer |
3(25.00) |
0.023 |
FRAP1,FGFR3,FZD8 |
| miR-222 |
hsa05200:Pathways in cancer |
5(7.25) |
0.013 |
ETS1,ARNT,CDKN1B,FOS,MAPK10 |
|
hsa04010:MAPK signaling pathway |
4(5.80) |
0.041 |
NTF3,PPP3R1,FOS,MAPK10 |
|
hsa04722:Neurotrophin signaling pathway |
3(4.35) |
0.050 |
YWHAG,NTF3,MAPK10 |
|
hsa04110:Cell cycle |
3(4.35) |
0.051 |
CDKN1C,CDKN1B,YWHAG |
|
hsa04360:Axon guidance |
3(4.35) |
0.054 |
GNAI2,PPP3R1,SEMA6D |
| miR-30a |
hsa05414:Dilated cardiomyopathy |
7(3.14) |
0.002 |
CACNB2,ADRB1,ITGB3,DMD,SGCB,ATP2A2,CACNA1C |
|
hsa04020:Calcium signaling pathway |
9(4.04) |
0.003 |
GRM5,ADRB2,CAMK2D,ADRB1,PPID,PLCB4,PLCG1,ATP2A2,CACNA1C |
|
hsa05412:Arrhythmogenic right ventricular cardiomyopathy (ARVC) |
6(2.69) |
0.004 |
CACNB2,ITGB3,DMD,SGCB,ATP2A2,CACNA1C |
|
hsa05410:Hypertrophic cardiomyopathy |
6(2.69) |
0.007 |
CACNB2,ITGB3,DMD,SGCB,ATP2A2,CACNA1C |
|
hsa04722:Neurotrophin signaling pathway |
7(3.14) |
0.008 |
RAP1B,IRS1,CAMK2D,CRKL,YWHAZ,PLCG1,MAP3K5 |
|
hsa04720:Long-term potentiation |
5(2.24) |
0.016 |
RAP1B,GRM5,CAMK2D,PLCB4,CACNA1C |
|
hsa04730:Long-term depression |
5(2.24) |
0.017 |
LYN,GRM5,GNAI2,PLCB4,GNAO1 |
|
hsa04930:Type II diabetes mellitus |
4(1.79) |
0.029 |
IRS1,SOCS3,SOCS1,CACNA1C |
|
hsa04360:Axon guidance |
6(2.69) |
0.037 |
GNAI2,UNC5D,PLXNA1,EPHB2,SEMA6D,SEMA3A |
|
hsa04120:Ubiquitin mediated proteolysis |
6(2.69) |
0.046 |
CUL2,NEDD4,UBE2I,SOCS3,NEDD4L,SOCS1 |
|
hsa04010:MAPK signaling pathway |
8(3.59) |
0.087 |
RAP1B,IL1A,CACNB2,MAP3K12,CRKL,RRAS2,CACNA1C,MAP3K5 |
